49439 Effect of Ruxolitinib Cream on Patient-Reported Outcomes (PROs) in Children Aged 2–<12 Years With Atopic Dermatitis (AD): Results From a Randomized, Double-Blind, Vehicle-Controlled Phase 3 Study (TRuE-AD3)

Authors

Andrea Zaenglein MD

Publication/Presentation Date

9-2024

Volume

91

Issue

3

First Page

190

Last Page

190

Published In/Presented At

https://doi.org/10.1016/j.jaad.2024.07.758

Department(s)

Department of Medicine Faculty

Document Type

Article